PTS Diagnostics Releases Updated A1C Home Monitoring System, Lowers Average Cost Per Test

PTS Diagnostics Releases Updated A1C Home Monitoring System, Lowers Average Cost Per Test

A1CNow® Self Check now comes with approximately one year’s worth of tests

INDIANAPOLIS (Oct. 24, 2018) – PTS Diagnostics, a U.S.–based manufacturer of point-of-caretesting devices, today announced that they are updating their at-home A1CNow Self Check system by doubling the number of A1C tests per package.

Moving from a two-count to a four-count system aligns with the American Diabetes Association’s recommendation of quarterly HbA1c testing in patients whose therapy has changed or who are not meeting glycemic goals.

“Accurate and affordable solutions at the point of care are essential for the management of diabetes and associated comorbidities,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “We’re a leader within the point-of-care industry and are proud to help to reduce the cost of in-home testing while adhering to the recommendations of valued industry associations.”

The increased number of tests may provide greater autonomy for people with diabetes while ensuring compliance with individualized treatment programs. This solution provides the patient with a method to inform the healthcare provider of their glycemic control without the need for frequent office visits.

The A1CNow Self Check is a home measurement system for HbA1c, the two to three-month average of one’s blood glucose. It is trusted throughout the United States’ medical community, provides results in five minutes, has more than a 12 month shelf-life at room temperature and comes with a monitor, test cartridges, fingerstick lancets, and blood collectors.

In addition to home usage, PTS Diagnostics envisions that providers will discover a niche for the updated product within the value-based healthcare system.

“The A1CNow Self Check can be used in conjunction with our PTS Connect® information management solutions to routinely monitor patients,” said Steve Riendeau, Chief Commercial Officer. Increased accessibility will help support new CMS initiatives related to remote patient monitoring and increase overall patient satisfaction.”

The four-count A1CNow Self Check is currently available online through Test Medical Symptoms At Home and in the professional setting through Cardinal Health, Fisher Scientific, Hanson Medical Systems, Henry Schein, and McKesson in the United States. The four-count is available in the European Union and will be rolled out to select countries and additional U.S. distributors in the coming months. Interested parties are encouraged to contact their local distributor, reach out to PTS Diagnostics via phone at 877-870-5610, or email PTS customer service at customerservice@ptsdiagnostics.com for more information.

About PTS Diagnostics:
Through its People, Technology and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices. Healthcare professionals have used our CardioChek® products to assess cardiovascular disease risks for more than 140 million patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. From our headquarters in the United States of America, we design, manufacture, and market our products to more than 140 countries around the globe. For more information, visit ptsdiagnostics.com.

Press Contact:
Ryan Simpson, Senior Marketing Associate
317-870-5610
rsimpson@ptsdiagnostics.com

PTS Diagnostics Enters Co-Branded Agreement With Rimidi

PTS Diagnostics Enters Co-Branded Agreement With Rimidi

Partnership with digital health leader allows for enhanced population-analytics, management of chronic conditions

INDIANAPOLIS – PTS Diagnostics, a U.S.-based manufacturer of point-of-care testing devices, today announced that they have entered into a contractual agreement with Atlanta-based digital health and analytics company, Rimidi.

The contract went into effect in October, 2018, and seeks to improve care and drive clinical efficiency by utilizing Connected Care, a digital condition management solution powered by Rimidi’s software. This aims to close gaps in care, and enable personalized management of diseases for individuals, population analytics for care teams, and clinical analytics for providers.

“PTS Diagnostics has spent considerable time and effort understanding our customers’ needs related to patient outcomes, workflow improvement, and maximizing value-based payment models,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “We’ve partnered with Rimidi to better serve our customers when it comes to improved patient and provider experience and outcomes at a lower cost.”

With unique digital dashboards for both patients and providers, Connected Care allows for enhanced patient monitoring and coaching. The joint offering of Connected Care and PTS Diagnostics A1CNow® and CardioChek® point-of-care solutions, enables the type of proactive population management required for value-based care models.

“Rimidi’s goal is to improve the experience for both patients with chronic conditions and their physicians and care teams, ultimately improving patient outcomes and lowering costs,” said Josh Claman, CEO of Rimidi. “We cannot do that without an ecosystem of strategic partnerships like this one with PTS Diagnostics.”

Unlike other freestanding chronic disease management platforms, Connected Care works seamlessly into the physician or care team’s workflow, integrating directly with providers’ Electronic Health Records (EHRs), leveraging emerging industry standards like SMART on FHIR. In addition, Connected Care features predictive medication modeling based on key markers from patient monitoring, enabling the potential for greater treatment plan adherence.

“Our customers count on us to partner with quality solutions-providers and PTS Diagnostics has a proven track record of delivering point-of-care technology of the highest quality,” said Jeff Stebbins, Head of Payer Strategy and Marketing. “We could not be prouder to partner with an innovator such as Rimidi, whose technology bridges the gap between population health and personalized medicine.”

This partnership is being unveiled in the United States and select foreign countries and will continue to grow as population health needs dictate. For more information, please reach out to PTS Diagnostics via phone at 877-870-5610, or email PTS Diagnostics customer service at customerservice@ptsdiagnostics.com for more information.

About PTS Diagnostics:
Through its People, Technology and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices. Healthcare professionals have used our CardioChek® products to assess cardiovascular disease risks for more than 140 million patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. From our headquarters in the United States of America, we design, manufacture, and market our products to more than 130 countries around the globe. For more information, visit ptsdiagnostics.com.

About Rimidi
Rimidi is addressing the healthcare problem of our generation- cardiometabolic diseases, which account for 70 percent of healthcare spend. Created by doctors, Rimidi enables efficient, personalized care to forward the future of healthcare. Rimidi’s platform derives actionable insight for clinicians and care teams from individual patient data, and integrates seamlessly into provider EHR systems, optimizing clinical workflow, improving health outcomes, and reducing costs. To learn more, visit Rimidi.com.

Press Contact:
Ryan Simpson, Senior Marketing Associate
317-870-5610
rsimpson@ptsdiagnostics.com

PTS Diagnostics Announces New Wellness Brand

PTS Diagnostics Announces New Wellness Brand

PreVantage family of solutions introduced for outcome-based healthcare

INDIANAPOLIS (Nov. 8, 2018) – PTS Diagnostics, a U.S.-based manufacturer of point-of-care testing devices, today announced the upcoming global launch of PreVantage, an all-encompassing family of solutions and partnerships aimed at addressing the growing demand for the achievement of positive population health outcomes.

The PreVantage brand was developed to address the complex needs of the multiple markets served by PTS Diagnostics. These configurable solutions are offered under singular umbrella brand and can be customized based upon unique customer needs.

“This brand marks our transition into becoming a global wellness solutions provider,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “For more than two decades, PTS Diagnostics has partnered with leaders largely in the health industry by providing products such as our A1CNow® systems and CardioChek® analyzers, which can allow healthcare professionals to monitor diabetes, as well as assess cardiovascular disease risk. We anticipate using PreVantage to build upon these existing relationships, continue our rapid expansion into new markets, and to help shape the future of healthcare.”

PreVantage allows PTS Diagnostics to strategically align with global healthcare changes through a unique focus on patient outcomes, lower healthcare costs, and improved clinician and patient experiences. 

“Outcomes are the new income in many healthcare models, and point-of-care testing aligns perfectly by rapidly and accurately providing results in minutes instead of days,” said Stephen Riendeau, Chief Commercial Officer of PTS Diagnostics. “In this complex global environment, no one product or company can meet the multitude of market demands, it will take an innovative approach which challenges the way that suppliers traditionally have partnered with customers. We’re hopeful that strategic partnerships associated with PreVantage will open doors in multiple market segments and help to improve the overall state of global healthcare.”

PreVantage is being unveiled in the United States and select countries in early 2019. It will continue to grow nationally as healthcare shifts from a fee-for-service model to merit-based incentivization. The brand will also mature globally as PTS Diagnostics assists with meeting unique healthcare needs abroad.

Interested parties are encouraged to reach out to PTS Diagnostics via phone at 877-870-5610, or email at customerservice@ptsdiagnostics.com for more information.

About PTS Diagnostics:
Through its People, Technology and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices. Healthcare professionals have used our CardioChek® products to assess cardiovascular disease risks for more than 140 million patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. From our headquarters in the United States of America, we design, manufacture, and market our products to more than 130 countries around the globe. For more information, visit ptsdiagnostics.com.

Press Contact:
Ryan Simpson, Senior Marketing Associate
317-870-5610 – rsimpson@ptsdiagnostics.com

PTS Diagnostics Enters Co-Branded Agreement with eTrueNorth

PTS Diagnostics Enters Co-Branded Agreement With eTrueNorth

Collaboration, titled PreVantage ConnectedQC, is addition to PreVantage family of solutions, provides quality control management and monitoring

INDIANAPOLIS – PTS Diagnostics, a U.S.-based manufacturer of point-of-care testing devices, today announced a multi-year, multi-faceted solution-based partnership with eTrueNorth, the premier integrated pharmacy-based clinical services network.

The contract will provide PreVantage customers with a co-branded quality control support software solution and other services, with the ultimate goals of closing gaps in care and supporting wellness screenings.

Powered by eTrueNorth, the partnership helps to form PreVantage ConnectedQC, a wellness solution that assists healthcare providers in managing their QC requirements in a manner consistent with current regulatory standards.

“This alliance is the latest win for PTS Diagnostics and the PreVantage brand,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “eTrueNorth is an industry trailblazer when it comes to driving access, quality, and affordability in healthcare. Their software and custom
voucher solutions and can help to close gaps in care.”

eTrueNorth’s innovative eLabNetwork® is composed of independent CLIA-waived laboratories located in retail pharmacies. Their voucher-based system enables access to health screenings across this extensive network of retail pharmacies for employee wellness program participants who work remotely or are unable to attend onsite screenings.

These wellness screenings use world-class point-of-care testing solutions from PTS Diagnostics and results are immediately shared with the participant and securely transferred to the employers’ health portal to ensure maximum participation.

“95 percent of the U.S. population lives within five miles of a retail pharmacy. Our aim is to equip these pharmacies with the technology they need to support screening events and wellness initiatives,” said Coral May, President of eTrueNorth. “The reliability of the point-of-care solutions offered by PTS Diagnostics is the perfect match for our suite of programs. We’re excited to work together to help shape the future of healthcare.”

This partnership is being unveiled in the United States and eventually in select foreign countries and will continue to grow as demand dictates. For more information, please reach out to PTS Diagnostics via phone at 877-870-5610, or email PTS Diagnostics customer service at
customerservice@ptsdiagnostics.com.

About PTS Diagnostics
Through its People, Technology and Service, PTS Diagnostics creates health innovation that  drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-ofcare medical devices. Healthcare professionals have used our CardioChek® products to assess cardiovascular disease risks for more than 140 million patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. From our headquarters in the United States of America, we design, manufacture, and market our products to more than 130 countries around the globe. For more information, visit ptsdiagnostics.com.

About PreVantage
PreVantage is a network of products, strategies, and partnerships aimed at helping healthcare organizations meet rapidly changing industry and consumer demands. By connecting innovations in technology, healthcare delivery, and payment models, PreVantage helps healthcare providers improve efficiency, lower costs, and increase reimbursements while delivering better health outcomes. More information is available
at ptsdiagnostics.com/PreVantage.

About eTrueNorth
eTrueNorth is an integrated, pharmacy-based, clinical services network. We help consumers fit healthcare into everyday life via the convenience and accessibility of retail pharmacy. Working with wellness vendors and Diabetes Prevention Programs, our network provides screenings with immediate test results for the participant and real-time data transmission to the vendor. Health plans benefit by our ability to engage plan members at the pharmacy counter and address gaps in care ranging from diabetes measures such as HbA1c to medication adherence and hypertension control. eTrueNorth’s integrated network is a tangible example of healthcare organizations working together to find creative solutions that drive access, quality and affordability. To learn more, visit www.eTrueNorth.com or contact CV Abdallah at (315) 374-7792 or cv@eTrueNorth.com.

Press Contact:
Ryan Simpson, Senior Marketing Associate
317-870-5610
rsimpson@ptsdiagnostics.com

PTS Diagnostics Expands PreVantage Family of Solutions

PTS Diagnostics Expands PreVantage Family of Solutions

Introduces tagline, solutions-based partnerships, sub-brands

INDIANAPOLIS (Dec. 20, 2018) – PTS Diagnostics, a U.S.-based manufacturer of point-of-care testing devices continues to grow their recently announced PreVantage™ brand through unique industry partnerships; additionally, “Outcomes are the new Income” has been selected as the brand’s U.S. slogan.

As U.S. healthcare continues to move away from traditional fee-for-service and toward merit-based incentivization, improved population healthcare outcomes will soon be the new means for provider income.

“PreVantage provides real-world solutions to real-world problems,” said Kevin Huttman, Executive Director, Marketing at PTS Diagnostics. “By teaming up with healthcare innovators, we’re able to offer both product and technology solutions that help support value-based care initiatives. It’s an exciting period of growth for PTS Diagnostics.”

To date, PTS Diagnostics is offering the following PreVantage solutions in addition to its industry-leading point-of-care solutions:

PreVantage ConnectedCare, Powered by Rimidi, is a population health chronic disease management solution created by medical professionals for medical professionals and patients that unlocks the meaning in patient data, enabling personalized, focused point of care solutions that can help improve outcomes and provide data which is critical to provider reimbursement maximization.

With unique digital dashboards for both patients and providers, PreVantage ConnectedCare allows for enhanced patient monitoring and coaching. Unlike many other freestanding chronic management platforms, it works seamlessly into the physician or care team’s workflow, integrating directly with providers’ Electronic Health Records (EHRs), leveraging emerging industry standards like SMART on FHIR.

PreVantage ConnectedQC, Powered by eTrueNorth, is a point of care quality control management solution which assists users of PTS Diagnostics solutions in managing their QC requirements in a manner consistent with current regulatory standards.

PTS Diagnostics’ collaboration with eTrueNorth also allows PreVantage customers preferred access to eTrueNorth’s eQC suite of policy and procedure and regulatory requirement management programs.

PTS Diagnostics and eTrueNorth have also partnered on the eLab Network pharmacy-based voucher program which involves a national network of pharmacy partners whose aim is to increase patient access and to ultimately close gaps in care. The solutions enable access to health screenings across an extensive network of pharmacies for employee wellness program participants who work remotely or are unable to attend onsite screenings.

In most cases, participating pharmacies use world-class point-of-care testing solutions from PTS Diagnostics and the results are immediately shared with the participant and securely transferred to the employers’ health portal or electronic medical record.

With full program availability in January 2019, the ever-expanding PreVantage brand is a combination of products, solutions, and partnerships that seek to help healthcare professionals inspire patients to live happier and healthier lives while increasing efficiency and maximizing reimbursement for healthcare providers.

PTS Connect® ScreenPro, powered by StatBridge, is being relaunched. PTS Diagnostics is introducing innovative acquisition programs as part of the PreVantage umbrella. This solution helps systems to manage population-based and employer health screening events while connecting PTS Diagnostics’ systems to data capture solutions.

Interested parties are encouraged to reach out to PTS Diagnostics via phone at 877-870-5610, or email at customerservice@ptsdiagnostics.com for more information.

About PTS Diagnostics
Through its People, Technology and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices. Healthcare professionals have used our CardioChek® products to assess cardiovascular disease risks for more than 140 million patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. From our headquarters in the United States of America, we design, manufacture, and market our products to more than 130 countries around the globe. For more information, visit ptsdiagnostics.com.

About PreVantage
PreVantage is a network of products, strategies, and partnerships aimed at helping healthcare organizations meet rapidly changing industry and consumer demands. By connecting innovations in technology, healthcare delivery, and payment models, PreVantage helps healthcare providers improve efficiency, lower costs, and increase reimbursements while delivering better health outcomes. More information is available at ptsdiagnostics.com/PreVantage.

Press Contact:
Ryan Simpson, Senior Marketing Associate
317-870-5610 – rsimpson@ptsdiagnostics.com